Patients with adenoid cystic carcinoma and MYB overexpression are included in the ongoing MYPHISMO trial with novel vaccination approach, used synergistically with programmed cell death protein 1 (PD-1) inhibitors [57]. The gene discussed is MYB; the disease is adenoid cystic carcinoma.